Skip to main content
Delfa

← All assets

ONO-2020

2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

2

Ongoing

2

Recruiting

1

Completed

0

Sites

131

Countries

2

Endpoints

38

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 38 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
2

Trials by status

Recruiting
1
Active, not recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
15
Other (unclassified)
7
Global cognition
6
Behavior / neuropsychiatric
4
Function / daily living
2
Caregiver / quality of life
2
Other clinical outcomes
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 10 of 38 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

4

Neuropsychiatric Inventory (NPI)Behavior

2

Mini-Mental State Examination (MMSE)Cognition

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

2 of 2

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT06881836A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

ONO-2020

Alzheimer’s disease

Alzheimer's diseasePh 2Active, not recruiting96Jul 2026-
NCT06803823A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

ONO-2020

Alzheimer’s disease

Alzheimer's diseasePh 2Recruiting38Dec 2026-

Showing 1-2 of 2 trials